SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance
Product revenue exceeded the warrant-call threshold, enabling a call that could bring up to $4.0 million in additional capital.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SINTX Technologies (NASDAQ: SINT) announced preliminary third-quarter revenue of $2.2 million, exceeding the high end of its previous guidance. Revenue for the quarter ended September 30, 2026 surpassed guidance of $0.9 million to $1.1 million, grew roughly 380% from Q2 and exceeded ten times the prior-year quarter. Aerospace subsidiaries of Fortune 500 companies accounted for most revenue. Shipments began against more than $3.2 million in previously announced purchase orders.
SINTX expects narrower losses than previous quarters and reiterated Q4 revenue guidance. Roughly $2.1 million in product revenue exceeded the $2.0 million quarterly trigger for calling Class B warrants. SINTX intends to call warrants covering approximately 1.88 million shares; full exercise could raise up to $4.0 million, but proceeds are not assured. Revenue is unaudited and subject to adjustment; final revenue could differ materially.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPreliminary Q3 revenue of $2.2 million exceeded $0.9 million–$1.1 million guidance, growing roughly 380% from Q2 and over tenfold year-over-year.
- Major point. Forward-looking: it has not happened yet and may not happen.Up to $4.0 million in additional capital could result if the Class B warrants are fully exercised. 27% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Narrower losses than previous quarters are expected from stronger-than-expected industrial ceramics sales.
- Moderate pointShipments began against more than $3.2 million in contract manufacturing purchase orders announced in June. 22% of market cap
- Minor pointRoughly $2.1 million in product revenue surpassed the $2.0 million quarterly warrant-call trigger.
- Minor pointCommercial infrastructure expanded during 2026 to support the silicon nitride orthopedic portfolio.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Approximately 1.88 million shares under Class B warrants could dilute holders; exercise price is the closing price immediately preceding the Call Notice.
- Minor pointWarrant exercise proceeds are not assured, despite the planned Call Notice.
- Minor point. Forward-looking: it has not happened yet and may not happen.Preliminary revenue is unaudited and subject to adjustment; final reported revenue could differ materially.
News Explained
SINTX says it intends to deliver the Class B warrant call notice with this release; the exercise price will be set by the prior trading day’s closing price, and warrants not exercised on time expire, so any resulting share issuance and proceeds depend on holder exercise.
Details
Market Reaction – SINT
On Oct 1, the day this news came out, the latest delayed price for SINT is 2.24% above the previous close. Argus tracked a trough of -13.0% from its starting point during tracking. Our momentum scanner has recorded 23 alerts for this stock so far that day. The latest delayed price is $2.28. Relative volume is very high at 3.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Preliminary Q3 revenue
- $2.2 million
- Third quarter 2026; above prior guidance
- Prior Q3 revenue guidance
- $0.9 million to $1.1 million
- Previously announced guidance range
- Quarter-over-quarter revenue growth
- Roughly 380%
- Q3 2026 versus Q2 2026
- Contract manufacturing purchase orders
- More than $3.2 million
- Orders announced in June; shipments began during Q3
- Product sales
- Roughly $2.1 million
- Q3 2026; exceeded the Call Right trigger
- Call Right trigger
- At least $2.0 million
- Product revenue during a fiscal quarter
- Class B warrants subject to call notice
- Approximately 1.88 million shares
- Aggregate shares underlying the warrants
- Potential warrant exercise proceeds
- Up to $4.0 million
- Conditional on full exercise; proceeds are not assured
Historical Context
-
Set Q3 revenue guidance at $0.9–$1.1 million and cited $3.2 million in industrial orders.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
warrants financial
form 8-k regulatory
exercise price financial
unaudited financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Third-quarter revenue grows roughly
Revenue milestone also enables Company to call Class B warrants
SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited revenue of
Sales of industrial parts to aerospace subsidiaries of Fortune 500 companies accounted for the majority of third-quarter revenue. During the quarter, SINTX began shipments against the more than
“We are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric Olson, Chairman and CEO of SINTX. “In addition to the significantly narrowed losses we expect to see as a result of these sales and nearly doubling the high end of the guidance we provided in August, our 2026 third-quarter revenue represents growth of roughly
During 2026, SINTX has expanded the commercial infrastructure supporting its silicon nitride orthopedic portfolio, including its FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System. SINTX continues to develop its silicon nitride SiNERGY™ technology platform across biocomposite and 3D printing capabilities, as well as its antimicrobial textiles as part of the overall platform for orthopedic, spine, craniofacial, dental, suture and wound-management applications.
Mr. Olson continued, “This quarter demonstrates our ability to turn industrial customer orders into revenue at scale through our U.S. manufacturing operations. Our focus now is on reliable delivery, repeat business and disciplined manufacturing costs. We see this execution as an important foundation for SINTX as we continue our transition towards a more diversified commercial-stage advanced materials company.”
Concurrent with issuing this press release on Form 8-K, the Company also intends to deliver a Call Notice to the holders of Class B Warrants to purchase an aggregate of approximately 1.88 million shares of the Company’s Common Stock. Roughly
*This amount represents preliminary recognized revenue for the quarter, while the Company is completing its quarter-end financial close and review procedures. The preliminary revenue figure is based on information currently available to management, is unaudited, and remains subject to adjustment. SINTX expects to provide complete third-quarter financial results in its forthcoming quarterly reporting. Final reported revenue could differ materially.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the Company’s expectations concerning its fourth-quarter 2026 revenue; anticipated operating results, including expectations regarding narrowed losses; the Company’s ability to achieve reliable delivery, repeat business and disciplined manufacturing costs; the continued development and commercialization of the Company’s silicon nitride technology platform and related applications; the Company’s transition toward a more diversified commercial-stage advanced materials company; the Company’s intention and ability to call the Class B Warrants; the potential exercise of such warrants by holders; and the amount and availability of any proceeds resulting from such exercises. The Company’s reported third-quarter 2026 revenue is preliminary and unaudited and remains subject to completion of the Company’s quarter-end financial close and review procedures. Final reported results may differ from the preliminary results described in this release, including as a result of adjustments identified during the closing and financial reporting process. Forward-looking statements are based on management’s current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the Company’s ability to successfully develop and commercialize its products and technologies; obtain and maintain applicable regulatory clearances or approvals; achieve market acceptance among surgeons, healthcare providers, distributors and other customers; substantiate anticipated product characteristics and performance; protect and enforce its intellectual property; manufacture products at commercial scale; satisfy customer orders on expected schedules; maintain manufacturing throughput and operational efficiencies; manage manufacturing and operating costs; successfully execute its strategic and commercial objectives; and the risks associated with the Class B Warrants, including that holders may not exercise the warrants and that the Company may receive less proceeds than anticipated or no proceeds at all, as well as the risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other SEC filings. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement, except as required by applicable law.
Company Contact:
Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much preliminary Q3 2026 revenue did SINTX report?
SINTX reported $2.2 million in preliminary, unaudited revenue for the quarter ended September 30, 2026. That exceeded its previous guidance of $0.9 million to $1.1 million. Revenue remains subject to adjustment while quarter-end financial close and review procedures are completed.
How much could SINTX raise from its planned Class B warrant call?
Full exercise of the Class B warrants under their terms could provide up to $4.0 million in additional capital. The planned call covers warrants to purchase approximately 1.88 million common shares. Exercise proceeds are not assured.
How is the exercise price set for SINTX's Class B warrant call, and what happens to unexercised warrants?
The exercise price is the common stock's closing price on the trading day immediately preceding the Call Notice, and warrants or portions not exercised in a timely manner automatically expire. SINTX intends to deliver the Call Notice concurrently with issuing the announcement on Form 8-K.